CN114269340A - Kcnt1抑制剂和使用方法 - Google Patents

Kcnt1抑制剂和使用方法 Download PDF

Info

Publication number
CN114269340A
CN114269340A CN202080047961.1A CN202080047961A CN114269340A CN 114269340 A CN114269340 A CN 114269340A CN 202080047961 A CN202080047961 A CN 202080047961A CN 114269340 A CN114269340 A CN 114269340A
Authority
CN
China
Prior art keywords
compound
alkyl
group
cycloalkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080047961.1A
Other languages
English (en)
Chinese (zh)
Inventor
G.马蒂内兹博特拉
A.M.格里芬
P.S.查里弗森
K.雷迪
M.K.M.卡利格
B.E.马伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Praxis Precision Medicines Inc
Original Assignee
Praxis Precision Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Precision Medicines Inc filed Critical Praxis Precision Medicines Inc
Priority to CN202510784123.7A priority Critical patent/CN120817941A/zh
Publication of CN114269340A publication Critical patent/CN114269340A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080047961.1A 2019-05-03 2020-05-01 Kcnt1抑制剂和使用方法 Pending CN114269340A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510784123.7A CN120817941A (zh) 2019-05-03 2020-05-01 Kcnt1抑制剂和使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962842849P 2019-05-03 2019-05-03
US62/842,849 2019-05-03
US202062982864P 2020-02-28 2020-02-28
US62/982,864 2020-02-28
PCT/US2020/031046 WO2020227101A1 (en) 2019-05-03 2020-05-01 Kcnt1 inhibitors and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510784123.7A Division CN120817941A (zh) 2019-05-03 2020-05-01 Kcnt1抑制剂和使用方法

Publications (1)

Publication Number Publication Date
CN114269340A true CN114269340A (zh) 2022-04-01

Family

ID=73051241

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080047961.1A Pending CN114269340A (zh) 2019-05-03 2020-05-01 Kcnt1抑制剂和使用方法
CN202510784123.7A Pending CN120817941A (zh) 2019-05-03 2020-05-01 Kcnt1抑制剂和使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510784123.7A Pending CN120817941A (zh) 2019-05-03 2020-05-01 Kcnt1抑制剂和使用方法

Country Status (17)

Country Link
US (1) US20220259193A1 (https=)
EP (1) EP3962481A4 (https=)
JP (2) JP7667573B2 (https=)
KR (1) KR20220016086A (https=)
CN (2) CN114269340A (https=)
AU (1) AU2020267356B2 (https=)
BR (1) BR112021022067A2 (https=)
CA (1) CA3139063A1 (https=)
CL (2) CL2021002877A1 (https=)
CO (1) CO2021016471A2 (https=)
EC (1) ECSP21087884A (https=)
IL (1) IL287768A (https=)
MX (1) MX2021013421A (https=)
PE (1) PE20220016A1 (https=)
SA (1) SA521430751B1 (https=)
SG (1) SG11202112158YA (https=)
WO (1) WO2020227101A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115443129A (zh) * 2020-02-28 2022-12-06 普拉西斯精密医药公司 Kcnt1抑制剂和使用方法
CN116813505A (zh) * 2023-06-29 2023-09-29 爱斯特（成都）生物制药股份有限公司 一种制备o-甲基-n-苄氧羰基-l-高丝氨酸的方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12590083B2 (en) 2019-01-25 2026-03-31 University Of Virginia Patent Foundation Inhibitors of spinster homolog 2 (SPNS2) for use in therapy
KR20250172745A (ko) * 2019-05-03 2025-12-09 프락시스 프리시젼 메디신즈, 인크. Kcnt1 억제제 및 사용 방법
EP4210824A1 (en) * 2020-09-09 2023-07-19 University of Virginia Patent Foundation Inhibitors of spinster homolog 2 (spns2) for use in therapy
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
TW202227424A (zh) * 2020-11-27 2022-07-16 大陸商瑞石生物醫藥有限公司 芳基或雜芳基取代５員芳雜環化合物及其用途
WO2022140547A2 (en) * 2020-12-22 2022-06-30 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2022231872A1 (en) * 2021-04-29 2022-11-03 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
EP4329735B1 (en) * 2021-04-29 2026-02-25 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2023211850A1 (en) * 2022-04-25 2023-11-02 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use
US20250360117A1 (en) * 2022-06-08 2025-11-27 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use
WO2025117662A1 (en) * 2023-11-29 2025-06-05 Actio Biosciences, Inc. Heterocyclic compounds useful as kcnt1 inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059269A2 (en) * 2001-12-21 2003-07-24 Bristol-Myers Squibb Company Acridone inhibitors of impdh enzyme
CN101096368A (zh) * 2004-02-18 2008-01-02 阿斯利康(瑞典)有限公司 新的杂多环化合物及其作为代谢型谷氨酸受体拮抗剂的用途
CN101790527A (zh) * 2006-07-20 2010-07-28 凯利普西斯公司 Rho激酶的苯并噻吩抑制剂
CN105263929A (zh) * 2013-03-14 2016-01-20 诺华股份有限公司 作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物
US20180072708A1 (en) * 2015-03-25 2018-03-15 National Center For Geriatrics And Gerontology Novel oxadiazole derivative and pharmaceutical containing same
WO2018187480A1 (en) * 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
US20190022039A1 (en) * 2016-03-30 2019-01-24 Ajinomoto Co., Inc. Compound having enhancing activity for glucagon-like peptide-1 receptor actions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP2005060255A (ja) * 2003-08-20 2005-03-10 Nippon Nohyaku Co Ltd カルボキサミド類及びこれを有効成分とする有害生物防除剤
ES2895174T3 (es) 2014-09-29 2022-02-17 Scripps Research Inst Moduladores del receptor de esfingosina-1-fosfato para el tratamiento de trastornos cardiopulmonares
JP7699836B2 (ja) * 2020-02-28 2025-06-30 プラクシス プレシジョン メディシンズ， インコーポレイテッド Ｋｃｎｔ１阻害剤、および使用方法
KR20230005168A (ko) * 2020-03-23 2023-01-09 프락시스 프리시젼 메디신즈, 인크. Kcnt1 억제제 및 사용 방법
CA3188825A1 (en) * 2020-07-06 2022-01-13 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
US11773088B2 (en) * 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
WO2022140547A2 (en) * 2020-12-22 2022-06-30 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
EP4329735B1 (en) * 2021-04-29 2026-02-25 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059269A2 (en) * 2001-12-21 2003-07-24 Bristol-Myers Squibb Company Acridone inhibitors of impdh enzyme
CN101096368A (zh) * 2004-02-18 2008-01-02 阿斯利康(瑞典)有限公司 新的杂多环化合物及其作为代谢型谷氨酸受体拮抗剂的用途
CN101790527A (zh) * 2006-07-20 2010-07-28 凯利普西斯公司 Rho激酶的苯并噻吩抑制剂
CN105263929A (zh) * 2013-03-14 2016-01-20 诺华股份有限公司 作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物
US20180072708A1 (en) * 2015-03-25 2018-03-15 National Center For Geriatrics And Gerontology Novel oxadiazole derivative and pharmaceutical containing same
US20190022039A1 (en) * 2016-03-30 2019-01-24 Ajinomoto Co., Inc. Compound having enhancing activity for glucagon-like peptide-1 receptor actions
WO2018187480A1 (en) * 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRAGA V M L等: "Synthesis of new 1, 2, 4-oxadiazoles carrying (1\'S, 2\'S)-t-butyloxycarbonyl-1-amino-2-methyl-1-butyl and (1\'S)-t-butyloxycarbonyl-1\'-amino-1\'-ethyl groups at C-5", JOURNAL OF THE BRAZILIAN CHEMICAL SOCIETY, vol. 15, no. 4, 31 August 2004 (2004-08-31), pages 603 - 607, XP093021400, DOI: 10.1590/S0103-50532004000400025 *
BRAGA, ANTONIO L.等: "\'One-Pot\'synthesis of chiral N-protected α-amino acid-derived 1, 2, 4-Oxadiazoles", SYNTHESIS, no. 2004, 30 November 2004 (2004-11-30), pages 1589 - 1594, XP002541366, DOI: 10.1055/S-2004-822391 *
RÉBECCA F POULAIN等: "Parallel synthesis of 1, 2, 4-oxadiazoles from carboxylic acids using an improved, uronium-based, activation", TETRAHEDRON LETTERS, vol. 42, no. 8, 19 February 2001 (2001-02-19), pages 1495 - 1498, XP002427070, DOI: 10.1016/S0040-4039(00)02293-0 *
STN REGISTRY数据库: "CAS号1338698-26-2", pages 1, Retrieved from the Internet <URL:https://www.stn.org> *
STN REGISTRY数据库: "CAS号1823229-23-7", pages 1, Retrieved from the Internet <URL:https://www.stn.org> *
STN REGISTRY数据库: "CAS号1824064-84-7", pages 1, Retrieved from the Internet <URL:https://www.stn.org> *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115443129A (zh) * 2020-02-28 2022-12-06 普拉西斯精密医药公司 Kcnt1抑制剂和使用方法
CN116813505A (zh) * 2023-06-29 2023-09-29 爱斯特（成都）生物制药股份有限公司 一种制备o-甲基-n-苄氧羰基-l-高丝氨酸的方法
CN116813505B (zh) * 2023-06-29 2025-09-02 爱斯特（成都）生物制药股份有限公司 一种制备o-甲基-n-苄氧羰基-l-高丝氨酸的方法

Also Published As

Publication number Publication date
JP2025102975A (ja) 2025-07-08
EP3962481A1 (en) 2022-03-09
CL2024002067A1 (es) 2024-12-13
ECSP21087884A (es) 2022-01-31
KR20220016086A (ko) 2022-02-08
EP3962481A4 (en) 2023-03-22
AU2020267356A1 (en) 2022-01-06
CO2021016471A2 (es) 2022-04-08
CA3139063A1 (en) 2020-11-12
MX2021013421A (es) 2022-02-11
JP7667573B2 (ja) 2025-04-23
SG11202112158YA (en) 2021-12-30
IL287768A (en) 2022-01-01
CN120817941A (zh) 2025-10-21
WO2020227101A1 (en) 2020-11-12
JP2022531388A (ja) 2022-07-06
PE20220016A1 (es) 2022-01-11
BR112021022067A2 (pt) 2022-05-17
CL2021002877A1 (es) 2022-08-12
SA521430751B1 (ar) 2024-02-01
AU2020267356B2 (en) 2025-04-24
US20220259193A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
CN114269340A (zh) Kcnt1抑制剂和使用方法
CN108047115B (zh) 经乙醛酰胺取代的吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
CN114206335A (zh) Kcnt1抑制剂和使用方法
HK1210030A1 (en) Sulfamoyl-aryamides and the use thereof as medicaments for the treatment of hepatitis b
TWI866940B (zh) 吡唑基-氨基-嘧啶基衍生物的苯甲醯胺及其組合物和方法
CN114173803A (zh) 氨基酸化合物的剂型和方案
CN109996541A (zh) N-酰基氨基酸化合物及其使用方法
TW201443046A (zh) 噻二唑類似物及治療ｓｍｎ缺乏相關症狀之方法
CN103781776A (zh) 用作端锚聚合酶抑制剂的新的2-哌啶-1-基-乙酰胺化合物
TW201429947A (zh) 昇糖素受體調節劑
CN105517993B (zh) 芳基酰胺激酶抑制剂
TW201609634A (zh) 吡咯啶基碸類視色素相關孤兒受體γ（ＲＯＲγ）調節劑
CN110545817B (zh) Gsk-3抑制剂
JP7824664B2 (ja) Ｋｃｎｔ１阻害剤及び使用方法
CN107074808A (zh) 作为食欲素‑1受体抑制剂的治疗性化合物
CN115443129A (zh) Kcnt1抑制剂和使用方法
CN110225912A (zh) Gsk-3抑制剂
CN112119077A (zh) 激酶抑制剂
CN114450005A (zh) 用于治疗神经障碍的化合物
HK40070149A (en) Dosage forms and regimens for amino acid compounds
HK40044282A (en) Amino acid compounds and methods of use
HK1255486A1 (en) Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
HK40014215A (en) Compounds and their methods of use
EA042124B1 (ru) Аминоимидазопиридазины в качестве ингибиторов киназ
HK1217326B (en) Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220401